{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:39:20Z","timestamp":1788471560191,"version":"build-2803163510"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272715"],"award-info":[{"award-number":["82272715"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Science and Technology Committee of China","award":["18411963000"],"award-info":[{"award-number":["18411963000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-025-02217-3","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T03:33:12Z","timestamp":1769225592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma"],"prefix":"10.1186","volume":"14","author":[{"given":"Ben","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-6889","authenticated-orcid":false,"given":"Miaoxia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"Supplement6","key":"2217_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M et al (2024) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2017\u20132021. Neuro Oncol 26(Supplement6):vi1\u2013vi85","journal-title":"Neuro Oncol"},{"issue":"10","key":"2217_CR2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","volume":"26","author":"JZ Wang","year":"2024","unstructured":"Wang JZ et al (2024) Meningioma: international consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol 26(10):1742\u20131780","journal-title":"Neuro Oncol"},{"issue":"1","key":"2217_CR3","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B et al (2024) Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 4(1):47\u201353","journal-title":"J Natl Cancer Cent"},{"issue":"8","key":"2217_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251","journal-title":"Neuro Oncol"},{"issue":"6","key":"2217_CR5","doi-asserted-by":"publisher","first-page":"e250265","DOI":"10.1148\/rycan.250265","volume":"7","author":"P Rai","year":"2025","unstructured":"Rai P et al (2025) Metastatic meningioma: neuroradiologic and molecular imaging perspectives. Radiol Imaging Cancer 7(6):e250265","journal-title":"Radiol Imaging Cancer"},{"issue":"11","key":"2217_CR6","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R et al (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23(11):1821\u20131834","journal-title":"Neuro Oncol"},{"issue":"12","key":"2217_CR7","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","volume":"29","author":"WC Chen","year":"2023","unstructured":"Chen WC et al (2023) Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med 29(12):3067\u20133076","journal-title":"Nat Med"},{"issue":"6123","key":"2217_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077\u20131080","journal-title":"Science"},{"issue":"10","key":"2217_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ng.3651","volume":"48","author":"VE Clark","year":"2016","unstructured":"Clark VE et al (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48(10):1253\u20131259","journal-title":"Nat Genet"},{"issue":"5","key":"2217_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/neuonc\/nov316","volume":"18","author":"M Abedalthagafi","year":"2016","unstructured":"Abedalthagafi M et al (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 18(5):649\u2013655","journal-title":"Neuro Oncol"},{"issue":"6","key":"2217_CR11","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3892\/ol.2014.2042","volume":"7","author":"M Bujko","year":"2014","unstructured":"Bujko M et al (2014) EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas. Oncol Lett 7(6):2019\u20132022","journal-title":"Oncol Lett"},{"issue":"1","key":"2217_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nou148","volume":"17","author":"TJ Kaley","year":"2015","unstructured":"Kaley TJ et al (2015) Phase II trial of Sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 17(1):116\u2013121","journal-title":"Neuro Oncol"},{"issue":"1","key":"2217_CR13","first-page":"vdac123","volume":"4","author":"P Kumthekar","year":"2022","unstructured":"Kumthekar P et al (2022) A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv 4(1):vdac123","journal-title":"Neurooncol Adv"},{"issue":"7874","key":"2217_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri F et al (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597(7874):119\u2013125","journal-title":"Nature"},{"issue":"5","key":"2217_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury A et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54(5):649\u2013659","journal-title":"Nat Genet"},{"issue":"5","key":"2217_CR16","doi-asserted-by":"publisher","first-page":"eabm6247","DOI":"10.1126\/sciadv.abm6247","volume":"8","author":"JCt Bayley","year":"2022","unstructured":"Bayley JCt et al (2022) Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Sci Adv 8(5):eabm6247","journal-title":"Sci Adv"},{"issue":"6","key":"2217_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41588-024-01747-1","volume":"56","author":"CG Lucas","year":"2024","unstructured":"Lucas CG et al (2024) Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution. Nat Genet 56(6):1121\u20131133","journal-title":"Nat Genet"},{"issue":"5","key":"2217_CR18","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/neuonc\/noae242","volume":"27","author":"AP Landry","year":"2025","unstructured":"Landry AP et al (2025) Development and validation of a molecular classifier of meningiomas. Neuro Oncol 27(5):1258\u20131269","journal-title":"Neuro Oncol"},{"key":"2217_CR19","doi-asserted-by":"publisher","first-page":"1186312","DOI":"10.3389\/fnins.2023.1186312","volume":"17","author":"Z Zhang","year":"2023","unstructured":"Zhang Z et al (2023) Inflammatory factors and risk of meningiomas: a bidirectional mendelian-randomization study. Front Neurosci 17:1186312","journal-title":"Front Neurosci"},{"issue":"2","key":"2217_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10143-021-01642-x","volume":"45","author":"J Haslund-Vinding","year":"2022","unstructured":"Haslund-Vinding J et al (2022) The role of systemic inflammatory cells in meningiomas. Neurosurg Rev 45(2):1205\u20131215","journal-title":"Neurosurg Rev"},{"key":"2217_CR21","doi-asserted-by":"publisher","first-page":"101509","DOI":"10.1016\/j.smim.2021.101509","volume":"54","author":"A Sehgal","year":"2021","unstructured":"Sehgal A, Irvine KM, Hume DA (2021) Functions of macrophage colony-stimulating factor (CSF1) in development, homeostasis, and tissue repair. Semin Immunol 54:101509","journal-title":"Semin Immunol"},{"issue":"11","key":"2217_CR22","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1093\/neuonc\/noab075","volume":"23","author":"J Yeung","year":"2021","unstructured":"Yeung J et al (2021) Targeting the CSF1\/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro Oncol 23(11):1922\u20131935","journal-title":"Neuro Oncol"},{"issue":"1","key":"2217_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/noab118","volume":"24","author":"WL Bi","year":"2022","unstructured":"Bi WL et al (2022) Activity of PD-1 Blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results. Neuro Oncol 24(1):101\u2013113","journal-title":"Neuro Oncol"},{"issue":"1","key":"2217_CR24","first-page":"vdae154","volume":"6","author":"D Limon","year":"2024","unstructured":"Limon D et al (2024) A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor. Neurooncol Adv 6(1):vdae154","journal-title":"Neurooncol Adv"},{"key":"2217_CR25","doi-asserted-by":"publisher","first-page":"215795","DOI":"10.1016\/j.canlet.2022.215795","volume":"543","author":"TW Chen","year":"2022","unstructured":"Chen TW et al (2022) Dual Inhibition of TGF\u03b2 signaling and CSF1\/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1. Cancer Lett 543:215795","journal-title":"Cancer Lett"},{"issue":"18","key":"2217_CR26","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y et al (2014) CSF1\/CSF1R Blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74(18):5057\u20135069","journal-title":"Cancer Res"},{"issue":"5","key":"2217_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune Response, TILs in invasive breast carcinoma and ductal carcinoma in Situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24(5):235\u2013251","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"2217_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11060-012-0989-y","volume":"111","author":"T Osawa","year":"2013","unstructured":"Osawa T et al (2013) Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema. J Neurooncol 111(1):49\u201357","journal-title":"J Neurooncol"},{"issue":"2","key":"2217_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11060-022-04127-z","volume":"161","author":"J Dos Santos Silva","year":"2023","unstructured":"Dos Santos Silva J et al (2023) Volumetric measurement of intracranial meningiomas: a comparison between linear, planimetric, and machine learning with multiparametric voxel-based morphometry methods. J Neurooncol 161(2):235\u2013243","journal-title":"J Neurooncol"},{"issue":"7","key":"2217_CR30","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-020-0932-2","volume":"26","author":"F Nassiri","year":"2020","unstructured":"Nassiri F et al (2020) Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. Nat Med 26(7):1044\u20131047","journal-title":"Nat Med"},{"issue":"1","key":"2217_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-022-01505-z","volume":"21","author":"W Li","year":"2022","unstructured":"Li W et al (2022) Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer 21(1):25","journal-title":"Mol Cancer"},{"issue":"1","key":"2217_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","volume":"21","author":"SN Lone","year":"2022","unstructured":"Lone SN et al (2022) Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer 21(1):79","journal-title":"Mol Cancer"},{"issue":"1","key":"2217_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12916-021-02193-0","volume":"20","author":"E Bouras","year":"2022","unstructured":"Bouras E et al (2022) Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. BMC Med 20(1):3","journal-title":"BMC Med"},{"issue":"1","key":"2217_CR34","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","volume":"13","author":"PK Brastianos","year":"2022","unstructured":"Brastianos PK et al (2022) Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun 13(1):1325","journal-title":"Nat Commun"},{"issue":"4","key":"2217_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3171\/jns.1973.38.4.0409","volume":"38","author":"DM Long","year":"1973","unstructured":"Long DM (1973) Vascular ultrastructure in human meningiomas and schwannomas. J Neurosurg 38(4):409\u2013419","journal-title":"J Neurosurg"},{"issue":"3","key":"2217_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/biomedicines6030086","volume":"6","author":"F Nigim","year":"2018","unstructured":"Nigim F et al (2018) Emerging medical treatments for meningioma in the molecular era. Biomedicines 6(3):86","journal-title":"Biomedicines"},{"issue":"7","key":"2217_CR37","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri F et al (2019) DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol 21(7):901\u2013910","journal-title":"Neuro Oncol"},{"issue":"7963","key":"2217_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41586-023-06085-6","volume":"618","author":"Z Zhu","year":"2023","unstructured":"Zhu Z et al (2023) Mitotic bookmarking by SWI\/SNF subunits. Nature 618(7963):180\u2013187","journal-title":"Nature"},{"issue":"6","key":"2217_CR39","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/1078-0432.CCR-23-2174","volume":"30","author":"TGP Gr\u00fcnewald","year":"2024","unstructured":"Gr\u00fcnewald TGP et al (2024) Translational aspects of epithelioid sarcoma: current consensus. Clin Cancer Res 30(6):1079\u20131092","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2217_CR40","doi-asserted-by":"publisher","first-page":"967","DOI":"10.4143\/crt.2023.1308","volume":"56","author":"HG Kang","year":"2024","unstructured":"Kang HG et al (2024) Molecular and treatment characteristics of SMARCB1 or SMARCA4-Deficient undifferentiated tumor: retrospective case series. Cancer Res Treat 56(3):967\u2013971","journal-title":"Cancer Res Treat"},{"issue":"4","key":"2217_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3892\/br.2025.1934","volume":"22","author":"EK Dwianingsih","year":"2025","unstructured":"Dwianingsih EK et al (2025) Molecular biomarkers in meningioma (Review). Biomed Rep 22(4):56","journal-title":"Biomed Rep"},{"issue":"8","key":"2217_CR42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI (2021) Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol 21(8):485\u2013498","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2217_CR43","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S et al (2021) A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184(3):792\u2013809e23","journal-title":"Cell"},{"issue":"2","key":"2217_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/jnen\/nlaa152","volume":"80","author":"J Yeung","year":"2021","unstructured":"Yeung J et al (2021) Spatially resolved and quantitative analysis of the immunological landscape in human meningiomas. J Neuropathol Exp Neurol 80(2):150\u2013159","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"2217_CR45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13046-025-03419-2","volume":"44","author":"T Zhang","year":"2025","unstructured":"Zhang T et al (2025) Tumour-associated macrophage infiltration differs in meningioma genotypes, and is important in tumour dynamics. J Exp Clin Cancer Res 44(1):162","journal-title":"J Exp Clin Cancer Res"},{"issue":"24","key":"2217_CR46","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1158\/0008-5472.CAN-21-3603","volume":"81","author":"WJ Ho","year":"2021","unstructured":"Ho WJ, Jaffee EM (2021) Macrophage-Targeting by CSF1\/1R Blockade in pancreatic cancers. Cancer Res 81(24):6071\u20136073","journal-title":"Cancer Res"},{"key":"2217_CR47","doi-asserted-by":"publisher","first-page":"148990","DOI":"10.1016\/j.gene.2024.148990","volume":"933","author":"P Sreesada","year":"2025","unstructured":"Sreesada P et al (2025) Matrix metalloproteinases: master regulators of tissue morphogenesis. Gene 933:148990","journal-title":"Gene"},{"issue":"15","key":"2217_CR48","doi-asserted-by":"publisher","first-page":"e2205525","DOI":"10.1002\/advs.202205525","volume":"10","author":"M Huang","year":"2023","unstructured":"Huang M et al (2023) Novel human meningioma organoids recapitulate the aggressiveness of the initiating cell subpopulations identified by ScRNA-Seq. Adv Sci (Weinh) 10(15):e2205525","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"2217_CR49","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11060-018-2803-y","volume":"138","author":"A Bunevicius","year":"2018","unstructured":"Bunevicius A et al (2018) Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients. J Neurooncol 138(2):351\u2013358","journal-title":"J Neurooncol"},{"issue":"1","key":"2217_CR50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13058-024-01925-3","volume":"26","author":"P De La Cruz","year":"2024","unstructured":"De La Cruz P et al (2024) NF-\u03baB associated markers of prognosis in early and metastatic triple negative breast cancer. Breast Cancer Res 26(1):175","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2217_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00234-020-02515-8","volume":"63","author":"CM Gill","year":"2021","unstructured":"Gill CM et al (2021) Peritumoral edema correlates with mutational burden in meningiomas. Neuroradiology 63(1):73\u201380","journal-title":"Neuroradiology"},{"issue":"2","key":"2217_CR52","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/neuonc\/noaa190","volume":"23","author":"L Joo","year":"2021","unstructured":"Joo L et al (2021) Extensive peritumoral edema and brain-to-tumor interface MRI features enable prediction of brain invasion in meningioma: development and validation. Neuro Oncol 23(2):324\u2013333","journal-title":"Neuro Oncol"},{"issue":"4","key":"2217_CR53","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s12094-022-03009-0","volume":"25","author":"B Fiani","year":"2023","unstructured":"Fiani B et al (2023) Peritumoral edema in meningiomas: pathophysiology, predictors, and principles for treatment. Clin Transl Oncol 25(4):866\u2013872","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"2217_CR54","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3171\/2017.11.JNS172265","volume":"130","author":"K Hess","year":"2019","unstructured":"Hess K et al (2019) Brain invasion and the risk of seizures in patients with meningioma. J Neurosurg 130(3):789\u2013796","journal-title":"J Neurosurg"},{"issue":"5","key":"2217_CR55","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/noab213","volume":"24","author":"J Driver","year":"2022","unstructured":"Driver J et al (2022) A molecularly integrated grade for meningioma. Neuro Oncol 24(5):796\u2013808","journal-title":"Neuro Oncol"},{"key":"2217_CR56","doi-asserted-by":"publisher","first-page":"823812","DOI":"10.3389\/fonc.2022.823812","volume":"12","author":"A Salvalaggio","year":"2022","unstructured":"Salvalaggio A et al (2022) Magnetic resonance imaging correlates of immune microenvironment in glioblastoma. Front Oncol 12:823812","journal-title":"Front Oncol"},{"issue":"1","key":"2217_CR57","doi-asserted-by":"publisher","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","volume":"5","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS et al (2016) Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 5(1):e1057388","journal-title":"Oncoimmunology"},{"issue":"3","key":"2217_CR58","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41(3):374\u2013403","journal-title":"Cancer Cell"},{"issue":"3","key":"2217_CR59","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S (2023) Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41(3):450\u2013465","journal-title":"Cancer Cell"},{"issue":"6","key":"2217_CR60","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/ncb3355","volume":"18","author":"T Welte","year":"2016","unstructured":"Welte T et al (2016) Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol 18(6):632\u2013644","journal-title":"Nat Cell Biol"},{"issue":"3","key":"2217_CR61","doi-asserted-by":"publisher","first-page":"e004384","DOI":"10.1136\/jitc-2021-004384","volume":"10","author":"Bitsch R","year":"2022","unstructured":"Bitsch R et al (2022) STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. J Immunother Cancer, 10(3):e004384","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2217_CR62","doi-asserted-by":"publisher","first-page":"e1440931","DOI":"10.1080\/2162402X.2018.1440931","volume":"7","author":"L Pinton","year":"2018","unstructured":"Pinton L et al (2018) Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma. Oncoimmunology 7(7):e1440931","journal-title":"Oncoimmunology"},{"issue":"4","key":"2217_CR63","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","volume":"22","author":"S Ostrand-Rosenberg","year":"2012","unstructured":"Ostrand-Rosenberg S et al (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22(4):275\u2013281","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2217_CR64","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K et al (2021) Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther 6(1):362","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2217_CR65","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA et al (2010) HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207(11):2439\u20132453","journal-title":"J Exp Med"},{"issue":"23","key":"2217_CR66","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1158\/0008-5472.CAN-21-1148","volume":"81","author":"JC Valencia","year":"2021","unstructured":"Valencia JC et al (2021) Myeloid-Derived suppressive cell expansion promotes melanoma growth and autoimmunity by inhibiting CD40\/IL27 regulation in macrophages. Cancer Res 81(23):5977\u20135990","journal-title":"Cancer Res"},{"issue":"6","key":"2217_CR67","doi-asserted-by":"publisher","first-page":"e006166","DOI":"10.1136\/jitc-2022-006166","volume":"11","author":"Y Wang","year":"2023","unstructured":"Wang Y et al (2023) G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition. J Immunother Cancer 11(6):e006166","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2217_CR68","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","volume":"66","author":"B Huang","year":"2006","unstructured":"Huang B et al (2006) Gr-1\u2009+\u2009CD115\u2009+\u2009immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66(2):1123\u20131131","journal-title":"Cancer Res"},{"issue":"1","key":"2217_CR69","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J et al (2025) Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther 10(1):268","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2217_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.CAN-09-1882","volume":"70","author":"PY Pan","year":"2010","unstructured":"Pan PY et al (2010) Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70(1):99\u2013108","journal-title":"Cancer Res"},{"issue":"4","key":"2217_CR71","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser EC, Mauri C (2015) Regulatory B cells: origin, phenotype, and function. Immunity 42(4):607\u2013612","journal-title":"Immunity"},{"issue":"2","key":"2217_CR72","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser SA et al (2024) Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol 21(2):147\u2013164","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2217_CR73","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.autrev.2011.11.018","volume":"11","author":"A Kessel","year":"2012","unstructured":"Kessel A et al (2012) Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev 11(9):670\u2013677","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2217_CR74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","volume":"10","author":"Y Zhou","year":"2025","unstructured":"Zhou Y et al (2025) Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity. Signal Transduct Target Ther 10(1):178","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2217_CR75","doi-asserted-by":"publisher","first-page":"e001946","DOI":"10.1136\/jitc-2020-001946","volume":"9","author":"Z Zhou","year":"2021","unstructured":"Zhou Z et al (2021) Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J Immunother Cancer 9(3):e001946","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2217_CR76","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","volume":"150","author":"SL Zhou","year":"2016","unstructured":"Zhou SL et al (2016) Tumor-Associated neutrophils recruit macrophages and T-Regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology 150(7):1646\u20131658e17","journal-title":"Gastroenterology"},{"issue":"7938","key":"2217_CR77","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue R et al (2022) Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612(7938):141\u2013147","journal-title":"Nature"},{"key":"2217_CR78","doi-asserted-by":"publisher","first-page":"104452","DOI":"10.1016\/j.ebiom.2023.104452","volume":"88","author":"A Mezheyeuski","year":"2023","unstructured":"Mezheyeuski A et al (2023) An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. EBioMedicine 88:104452","journal-title":"EBioMedicine"},{"issue":"1","key":"2217_CR79","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31\u201346","journal-title":"Cancer Discov"},{"issue":"1","key":"2217_CR80","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","volume":"10","author":"C Lee","year":"2025","unstructured":"Lee C et al (2025) Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. Signal Transduct Target Ther 10(1):170","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"2217_CR81","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182\u20131186","journal-title":"N Engl J Med"},{"issue":"8","key":"2217_CR82","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX et al (2022) Molecular correlates of clinical response and resistance to Atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 28(8):1599\u20131611","journal-title":"Nat Med"},{"issue":"9","key":"2217_CR83","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00011-024-01907-3","volume":"73","author":"O Sezginer","year":"2024","unstructured":"Sezginer O, Unver N (2024) Dissection of pro-tumoral macrophage subtypes and immunosuppressive cells participating in M2 polarization. Inflamm Res 73(9):1411\u20131423","journal-title":"Inflamm Res"},{"issue":"2","key":"2217_CR84","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10014-010-0012-2","volume":"28","author":"V Barresi","year":"2011","unstructured":"Barresi V (2011) Angiogenesis in meningiomas. Brain Tumor Pathol 28(2):99\u2013106","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"2217_CR85","first-page":"vdae128","volume":"6","author":"S Faye Borenstein","year":"2024","unstructured":"Faye Borenstein S et al (2024) Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria. Neurooncol Adv 6(1):vdae128","journal-title":"Neurooncol Adv"},{"issue":"9","key":"2217_CR86","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3390\/curroncol32090516","volume":"32","author":"DC Nguyen","year":"2025","unstructured":"Nguyen DC et al (2025) A retrospective study on prognostic factors and systemic treatments of refractory meningiomas. Curr Oncol 32(9):516","journal-title":"Curr Oncol"},{"key":"2217_CR87","doi-asserted-by":"publisher","first-page":"737523","DOI":"10.3389\/fonc.2021.737523","volume":"11","author":"W Hong","year":"2021","unstructured":"Hong W et al (2021) Case report: identification of a novel GNAS mutation and 1p\/22q Co-Deletion in a patient with multiple recurrent meningiomas sensitive to Sunitinib. Front Oncol 11:737523","journal-title":"Front Oncol"},{"issue":"1","key":"2217_CR88","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41590-022-01373-1","volume":"24","author":"MJ Kim","year":"2023","unstructured":"Kim MJ et al (2023) Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells. Nat Immunol 24(1):148\u2013161","journal-title":"Nat Immunol"},{"issue":"10","key":"2217_CR89","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.4049\/jimmunol.2001334","volume":"207","author":"SC Vick","year":"2021","unstructured":"Vick SC et al (2021) Anti-PD-1 checkpoint therapy can promote the function and survival of regulatory T cells. J Immunol 207(10):2598\u20132607","journal-title":"J Immunol"},{"issue":"20","key":"2217_CR90","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T et al (2019) PD-1(+) regulatory T cells amplified by PD-1 Blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A 116(20):9999\u201310008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2217_CR91","doi-asserted-by":"publisher","first-page":"e70659","DOI":"10.1111\/cns.70659","volume":"31","author":"Y Wang","year":"2025","unstructured":"Wang Y et al (2025) Phase 2 trial of PD-1 inhibitor sintilimab in Recurrent\/Progressive meningioma. CNS Neurosci Ther 31(12):e70659","journal-title":"CNS Neurosci Ther"},{"issue":"11","key":"2217_CR92","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1200\/JCO.19.02394","volume":"38","author":"AZ Dudek","year":"2020","unstructured":"Dudek AZ et al (2020) Phase Ib\/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003. J Clin Oncol 38(11):1138\u20131145","journal-title":"J Clin Oncol"},{"issue":"2","key":"2217_CR93","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B (2023) Combination immunotherapy for hepatocellular carcinoma. J Hepatol 79(2):506\u2013515","journal-title":"J Hepatol"},{"issue":"1","key":"2217_CR94","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-023-01731-x","volume":"9","author":"Y Huang","year":"2024","unstructured":"Huang Y et al (2024) QL1706 (anti-PD-1 IgG4\/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal Transduct Target Ther 9(1):23","journal-title":"Signal Transduct Target Ther"},{"key":"2217_CR95","doi-asserted-by":"publisher","first-page":"1496611","DOI":"10.3389\/fonc.2025.1496611","volume":"15","author":"C Song","year":"2025","unstructured":"Song C et al (2025) PD-1\/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1\/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis. Front Oncol 15:1496611","journal-title":"Front Oncol"},{"issue":"1","key":"2217_CR96","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X et al (2024) Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer 23(1):175","journal-title":"Mol Cancer"},{"issue":"16","key":"2217_CR97","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/0008-5472.CAN-20-3929","volume":"81","author":"SB Kemp","year":"2021","unstructured":"Kemp SB et al (2021) Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-\u03baB-Mediated production of CXCL1. Cancer Res 81(16):4305\u20134318","journal-title":"Cancer Res"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02217-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02217-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02217-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:02:23Z","timestamp":1772625743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-025-02217-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2217"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02217-3","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All hospitalized patients admitted into Changhai hospital routinely signed a written waiver to articulate their willingness to contribute to research projects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}